Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CTx-1301 ADHD Drug Progress

Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING), focusing on the company's fourth quarter 2025 update regarding its ADHD drug candidate CTx-1301. The analysis indicates that regulatory focus has shifted primarily to manufacturing, or Chemistry, Manufacturing, and Controls (CMC), rather than clinical performance or safety concerns. This positioning suggests the remaining work involves addressable process validation instead of fundamental clinical risks associated with the product profile.

The New Drug Application (NDA) for CTx-1301 remains under review by the U.S. Food and Drug Administration (FDA) via the 505(b)(2) regulatory pathway. While regulatory timing may experience shifts due to the manufacturing validation requirements, approval remains likely according to the analysis. The company's recent financing activities, intellectual property progress, and commercial buildout efforts continue to support the broader investment thesis for Cingulate.

Following a $12 million Private Investment in Public Equity (PIPE) financing completed in February 2026, Cingulate Inc. reports a pro forma cash balance of approximately $23 million. Stonegate Capital Partners estimates this provides financial runway into late 2026. Combined with ongoing access to capital through its At-The-Market (ATM) and Equity Line of Credit (ELOC) facilities, the firm believes Cingulate is positioned to fund ongoing regulatory and manufacturing activities as it works toward resolving the remaining CMC items.

The market opportunity for CTx-1301 is significant within the large ADHD treatment market. The analysis notes that capturing just approximately 1% market share could translate to roughly $250 million in revenue potential for the drug. CTx-1301 primarily targets the booster-dose segment of the ADHD market, as previously disclosed by the company. This focus on a specific treatment niche within a broader therapeutic area represents a strategic commercial approach. For more detailed information, the full announcement from Stonegate Capital Partners is available at https://www.stonegateinc.com.